- Home
- STEC vs SYBX Comparison
STEC vs SYBX Comparison
Compare STEC & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEC
- SYBX
- Stock Information
- Founded
- STEC 2006
- SYBX N/A
- Country
- STEC China
- SYBX United States
- Employees
- STEC N/A
- SYBX N/A
- Industry
- STEC
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- STEC
- SYBX Health Care
- Exchange
- STEC NYSE
- SYBX Nasdaq
- Market Cap
- STEC 19.0M
- SYBX 16.5M
- IPO Year
- STEC 2021
- SYBX N/A
- Fundamental
- Price
- STEC $1.31
- SYBX $1.16
- Analyst Decision
- STEC
- SYBX
- Analyst Count
- STEC 0
- SYBX 0
- Target Price
- STEC N/A
- SYBX N/A
- AVG Volume (30 Days)
- STEC 42.6K
- SYBX 6.3K
- Earning Date
- STEC 04-15-2025
- SYBX 03-06-2025
- Dividend Yield
- STEC N/A
- SYBX N/A
- EPS Growth
- STEC N/A
- SYBX N/A
- EPS
- STEC N/A
- SYBX N/A
- Revenue
- STEC $260,474,693.00
- SYBX $8,000.00
- Revenue This Year
- STEC $9.76
- SYBX N/A
- Revenue Next Year
- STEC $15.85
- SYBX N/A
- P/E Ratio
- STEC N/A
- SYBX N/A
- Revenue Growth
- STEC N/A
- SYBX N/A
- 52 Week Low
- STEC $0.20
- SYBX $1.10
- 52 Week High
- STEC $3.25
- SYBX $1.96
- Technical
- Relative Strength Index (RSI)
- STEC 48.81
- SYBX 30.45
- Support Level
- STEC $1.21
- SYBX $1.27
- Resistance Level
- STEC $1.54
- SYBX $1.26
- Average True Range (ATR)
- STEC 0.12
- SYBX 0.05
- MACD
- STEC -0.04
- SYBX -0.01
- Stochastic Oscillator
- STEC 30.30
- SYBX 25.21
About STEC SANTECH HOLDINGS LIMITED
Santech Holdings Ltd is a customer based technology company. The company is engaged in exploring new opportunities in technology that includes new retail, social e-commerce, metaverse and others.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.